ZA973495B - Matrix tablet allowing the prolonged release of the sodium salt of tianeptine after administration by the oral route. - Google Patents

Matrix tablet allowing the prolonged release of the sodium salt of tianeptine after administration by the oral route.

Info

Publication number
ZA973495B
ZA973495B ZA9703495A ZA973495A ZA973495B ZA 973495 B ZA973495 B ZA 973495B ZA 9703495 A ZA9703495 A ZA 9703495A ZA 973495 A ZA973495 A ZA 973495A ZA 973495 B ZA973495 B ZA 973495B
Authority
ZA
South Africa
Prior art keywords
tianeptine
administration
sodium salt
oral route
prolonged release
Prior art date
Application number
ZA9703495A
Other languages
English (en)
Inventor
Bruno Huet De Barochez
Patrick Wuthrich
Original Assignee
Adir
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adir filed Critical Adir
Publication of ZA973495B publication Critical patent/ZA973495B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cephalosporin Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA9703495A 1996-04-24 1997-04-23 Matrix tablet allowing the prolonged release of the sodium salt of tianeptine after administration by the oral route. ZA973495B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9605174A FR2747921B1 (fr) 1996-04-24 1996-04-24 Comprime matriciel permettant la liberation prolongee du sel de sodium de tianeptine apres administration par voie orale

Publications (1)

Publication Number Publication Date
ZA973495B true ZA973495B (en) 1997-11-18

Family

ID=9491549

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9703495A ZA973495B (en) 1996-04-24 1997-04-23 Matrix tablet allowing the prolonged release of the sodium salt of tianeptine after administration by the oral route.

Country Status (18)

Country Link
US (1) US5888542A (xx)
EP (1) EP0803253B1 (xx)
JP (1) JPH1036268A (xx)
CN (1) CN1116029C (xx)
AT (1) ATE205715T1 (xx)
AU (1) AU719822B2 (xx)
CA (1) CA2203310C (xx)
DE (1) DE69706748T2 (xx)
DK (1) DK0803253T3 (xx)
ES (1) ES2164310T3 (xx)
FR (1) FR2747921B1 (xx)
GR (1) GR3037043T3 (xx)
HU (1) HU224192B1 (xx)
NO (1) NO315407B1 (xx)
NZ (1) NZ314662A (xx)
PL (1) PL188135B1 (xx)
PT (1) PT803253E (xx)
ZA (1) ZA973495B (xx)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2791891A1 (fr) * 1999-04-07 2000-10-13 Adir Utilisation de la tianeptine pour l'obtention de medicaments destines au traitement des pathologies de la neurodegenerescence
US6683072B1 (en) 2003-02-04 2004-01-27 Vela Pharmaceuticals, Inc. Compositions and methods for treatment of irritable bowel syndrome and nonulcer dyspepsia
ES2336913T3 (es) * 2003-08-08 2010-04-19 Biovail Laboratories International Srl Comprimido de liberacion modificada de hidrocloruro de bupropion.
US20050227961A1 (en) * 2004-04-08 2005-10-13 Vela Pharmaceuticals, Inc. Compositions and methods for treatment of neuropathic pain, fibromyalgia and chronic fatigue syndrome
US9314469B2 (en) 2008-05-05 2016-04-19 Tonix Pharma Holdings Limited Method for treating neurocognitive dysfunction
US8198268B2 (en) 2008-10-31 2012-06-12 Janssen Biotech, Inc. Tianeptine sulfate salt forms and methods of making and using the same
US8355927B2 (en) 2010-11-05 2013-01-15 Genomind, Llc Neuropsychiatric test reports
WO2010138796A2 (en) * 2009-05-29 2010-12-02 Genomind, Llc Methods for assessment and treatment of depression via utilization of single nucleotide polymorphisms analysis
US20110237537A1 (en) * 2009-05-29 2011-09-29 Lombard Jay L Methods for assessment and treatment of mood disorders via single nucleotide polymorphisms analysis
KR20120092993A (ko) * 2011-02-14 2012-08-22 지엘팜텍 주식회사 티아넵틴 또는 이의 약제학적으로 허용되는 염을 포함하는 경구투여용 서방성 정제
PL2561864T3 (pl) * 2011-08-25 2015-05-29 Zakl Farmaceutyczne Polpharma Sa Tabletka powlekana zawierająca tianeptynę i sposób jej otrzymywania
KR101136976B1 (ko) * 2011-09-06 2012-05-30 건일제약 주식회사 티아넵틴 또는 그의 염을 포함하는 탈모증의 예방 또는 치료용 약학 조성물
GB201208315D0 (en) 2012-05-11 2012-06-27 Numedicus Ltd Pharmaceutical methods and compositions
CN104031005B (zh) * 2014-05-30 2016-04-27 济南诚汇双达化工有限公司 一种噻萘普汀钠中间体的制备方法
KR20180101307A (ko) 2018-09-04 2018-09-12 지엘팜텍주식회사 티아넵틴 또는 이의 약제학적으로 허용되는 염을 포함하는 경구투여용 서방성 정제
KR20200104265A (ko) 2020-08-21 2020-09-03 지엘팜텍주식회사 티아넵틴 또는 이의 약제학적으로 허용되는 염을 포함하는 경구투여용 서방성 정제
WO2024206520A1 (en) 2023-03-27 2024-10-03 Tonix Pharmaceuticals Holding Corp. (s)-tianeptine and use in treating disorders and conditions associated with peroxisome proliferator-activated receptor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5446070A (en) * 1991-02-27 1995-08-29 Nover Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
FR2635461B1 (fr) * 1988-08-18 1992-01-17 Adir Utilisation de derives tricycliques pour l'obtention de medicaments destines au traitement du stress
FR2716623B1 (fr) * 1994-02-25 1996-08-23 Adir Utilisation d'un dérivé tricyclique pour l'obtention de médicaments destinés au traitement des troubles mnémo-cognitifs.

Also Published As

Publication number Publication date
PL188135B1 (pl) 2004-12-31
FR2747921B1 (fr) 1998-10-30
HU224192B1 (hu) 2005-06-28
ES2164310T3 (es) 2002-02-16
HUP9700806A3 (en) 2000-01-28
AU1904197A (en) 1997-10-30
NO971860L (no) 1997-10-27
NO971860D0 (no) 1997-04-23
NZ314662A (en) 1998-12-23
NO315407B1 (no) 2003-09-01
DE69706748T2 (de) 2002-07-04
DK0803253T3 (da) 2001-11-19
CA2203310A1 (fr) 1997-10-24
AU719822B2 (en) 2000-05-18
US5888542A (en) 1999-03-30
PT803253E (pt) 2001-12-28
CA2203310C (fr) 2001-10-23
PL319627A1 (en) 1997-10-27
ATE205715T1 (de) 2001-10-15
JPH1036268A (ja) 1998-02-10
HU9700806D0 (en) 1997-06-30
CN1116029C (zh) 2003-07-30
DE69706748D1 (de) 2001-10-25
HUP9700806A2 (hu) 1998-10-28
GR3037043T3 (en) 2002-01-31
CN1168792A (zh) 1997-12-31
EP0803253A1 (fr) 1997-10-29
EP0803253B1 (fr) 2001-09-19
FR2747921A1 (fr) 1997-10-31

Similar Documents

Publication Publication Date Title
ZA973495B (en) Matrix tablet allowing the prolonged release of the sodium salt of tianeptine after administration by the oral route.
ZA959367B (en) Melt-extrusion multiparticulates
HUP0001894A3 (en) Pharmaceutical composition for oral administration of a n-piperidino-3-pyrazolecarboxamide derivative, its salts and their solvates
PT781550E (pt) Composicao farmaceutica bioadesiva para a libertacao controlada de principios activos
AU7052698A (en) Pharmaceutical composition for oral administration of a n-piperidino- 3-pyrazolecarboxamide derivative, its salts and their solvates
EP0802814A4 (en) BIT BLOCK FOR AN ENDOTRACHEAL TUBE
AU6132496A (en) Piperidine and morpholine derivatives and their use as therapeutic agents
AU6132596A (en) Piperidine and morpholine derivatives and their use as therapeutic agents
AU651894B2 (en) Matrix tablet permitting the sustained release of indapamide after oral administration
DE59712959D1 (de) Orale pharmazeutische zubereitung enthaltend ibandronat
HUP9902194A2 (hu) Dibenzo-[b,f][1,4]tiazepin-származékot tartalmazó gyógyászati készítmények
BR9917012A (pt) Comprimido matricial, permitindo a liberação prolongada de gliclazida, após administração por via oral
FI951357A0 (fi) Farmaseuttiset koostumukset, jotka mahdollistavat trimetatsidiinin hidastetun vapautumisen oraalisen annostuksen jälkeen
EP0953359A4 (en) PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION
FR2745500B1 (fr) Formulations pharmaceutiques a liberation prolongee contenant de la mizolastine
PL325509A1 (en) Therapeutic agent for oral administration
AU7266396A (en) Foot orthoses supply system